Hardcover. Condition: Brand New. 309 pages. 9.25x7.50x0.71 inches. In Stock.
Seller: Majestic Books, Hounslow, United Kingdom
Condition: New.
Condition: New.
Language: English
Published by Elsevier Science Publishing Co Inc, 2021
ISBN 10: 0128225270 ISBN 13: 9780128225271
Seller: THE SAINT BOOKSTORE, Southport, United Kingdom
£ 144.90
Quantity: Over 20 available
Add to basketHardback. Condition: New. New copy - Usually dispatched within 4 working days.
Seller: Biblios, Frankfurt am main, HESSE, Germany
Condition: New.
Language: English
Published by Nova Science Pub Inc, 2011
ISBN 10: 1616689641 ISBN 13: 9781616689643
Seller: Wize Books USA, Davis, CA, U.S.A.
Hardcover. Condition: New. New Hardcover printed hardcover - No dj issued: --Shrink Wrapped:
Seller: Brook Bookstore On Demand, Napoli, NA, Italy
Condition: new. Questo è un articolo print on demand.
Language: English
Published by Elsevier Science Mär 2021, 2021
ISBN 10: 0128225270 ISBN 13: 9780128225271
Seller: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Germany
Buch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -New Targeting in The Reversal of Resistant Glioblastomas discusses alternative treatment strategies that not only target tumor cells but also target the tumor microenvironment, metabolic pathways and interaction of cytokines in tumor cells. The current treatment for primary and recurrent glioblastomas is failing because clinicians are not considering the effect of bone marrow derived cells to the development of resistance to clinically practiced therapies. This book helps readers rethink treatment strategies to successfully fight glioblastomas. It is a valuable resource for cancer researchers, clinicians, graduate students and other members of the biomedical field. 202 pp. Englisch.
Seller: AHA-BUCH GmbH, Einbeck, Germany
Buch. Condition: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - New Targeting in The Reversal of Resistant Glioblastomas discusses alternative treatment strategies that not only target tumor cells but also target the tumor microenvironment, metabolic pathways and interaction of cytokines in tumor cells. The current treatment for primary and recurrent glioblastomas is failing because clinicians are not considering the effect of bone marrow derived cells to the development of resistance to clinically practiced therapies. This book helps readers rethink treatment strategies to successfully fight glioblastomas. It is a valuable resource for cancer researchers, clinicians, graduate students and other members of the biomedical field.